rs1800588 — LIPC -514C>T

Promoter variant that reduces hepatic lipase activity, raising HDL-C levels but shifting to larger, less protective HDL particles with a genotype-specific dietary fat response

See your personal result for LIPC

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

Hepatic Lipase — When Higher HDL Is Not Simply Better

Hepatic lipase (HL) is the enzyme that finishes the job [lipoprotein lipase | LPL, which works in peripheral tissues] starts. After LPL strips triglycerides from VLDL particles in muscle and fat, remnant IDL and HDL2 particles arrive at the liver surface where HL hydrolyzes their remaining triglycerides and phospholipids. This remodeling converts buoyant, cholesterol-rich HDL2 particles into smaller, denser HDL3 particles and returns cholesterol to the liver for excretion. HL is therefore a central regulator of HDL particle size, subclass distribution, and reverse cholesterol transport capacity.

The rs1800588 variant sits at position -514 in the LIPC promoter on chromosome 15q22, in a region that controls how much hepatic lipase the liver makes. It sits in near-perfect linkage disequilibrium11 near-perfect linkage disequilibrium
LD r²≈1.0 with rs2070895 (-250G>A), rs1077835 (-763A>G), and rs1077834 (-710C>T) — meaning these four variants almost always travel together as a haplotype, collectively accounting for 20–30% of individual variation in HL activity22 20–30% of individual variation in HL activity.

The Mechanism

The T allele at -514 reduces transcription of the LIPC gene, leading to lower hepatic lipase protein in the liver and consequently lower HL activity in the bloodstream. With less HL activity, the remodeling of HDL2 to HDL3 is slowed, so large HDL2 particles accumulate in circulation. This is why T allele carriers show higher total HDL-C on a standard lipid panel — they are retaining more of the buoyant, cholesterol-loaded HDL2 subclass.

The clinical nuance is important: high HDL-C from HL deficiency is not the same as high HDL-C from robust reverse cholesterol transport33 high HDL-C from HL deficiency is not the same as high HDL-C from robust reverse cholesterol transport
HL-generated small HDL3 particles are actually more efficient at picking up cholesterol from peripheral tissues. The larger HDL2 particles that accumulate in T carriers may be less functional as cholesterol acceptors despite appearing more abundant on a lipid panel.

A second effect runs in parallel: reduced HL activity also slows the clearance of IDL and VLDL remnants, contributing to higher total cholesterol and triglycerides in TT homozygotes — an atherogenic backdrop that partially offsets the higher nominal HDL-C.

The Evidence

The meta-analysis by Murtagh et al. (2004)44 meta-analysis by Murtagh et al. (2004) synthesized 25 studies covering more than 24,000 individuals and established the quantitative landscape. Each additional T allele reduced HL activity by approximately 5.8 mmol/L·h (CT vs CC, p<0.001), with TT showing a reduction of 11.1 mmol/L·h versus CC. HDL-C increased in a dose-dependent fashion: CT carriers averaged +0.04 mmol/L (+1.5 mg/dL) and TT carriers +0.09 mmol/L (+3.5 mg/dL) compared to CC homozygotes.

The critical gene-diet interaction emerged from the Framingham Heart Study (Tucker et al., 2002)55 Framingham Heart Study (Tucker et al., 2002), which followed 2,130 adults with dietary fat assessments. Among subjects eating less than 30% of calories from fat, TT individuals had the highest HDL-C. But when dietary fat exceeded 30% of calories — particularly from saturated and monounsaturated fat — the HDL advantage of TT genotype disappeared entirely, and TT subjects showed the lowest HDL-C among the three genotypes. A crossover randomized trial in Caribbean Hispanics (2017)66 crossover randomized trial in Caribbean Hispanics (2017) replicated this: CC and CT carriers had higher HDL-C on a Western-style high-fat diet, while TT individuals showed no diet-dependent HDL change. In a cross-sectional analysis of women, saturated fat was unfavorably associated with both HDL-C and triglycerides specifically in TT carriers.

The exercise data (n=76, overweight adults aged 50–75) showed that aerobic training improved LPL activity and lowered VLDL-TG in CC subjects by 22%77 aerobic training improved LPL activity and lowered VLDL-TG in CC subjects by 22%, while CT subjects showed increased HL activity after training but smaller improvements in HDL-C and VLDL-TG. A large cohort study of 14,000+ women88 large cohort study of 14,000+ women confirmed that physical activity amplified the HDL-C benefit of carrying the T allele — but notably found no reduction in myocardial infarction risk from the LIPC variant regardless of activity level. This distinguishes LIPC from CETP variants, where HDL-C raises do translate to MI protection.

In a Mexican population of 1,468 subjects, TT homozygotes showed increased risk for type 2 diabetes (OR 1.42)99 type 2 diabetes (OR 1.42), hypertriglyceridemia (OR 1.36), and coronary artery calcification (OR 1.44), alongside reduced risk of low HDL — reflecting the mixed cardiometabolic profile this variant creates.

Practical Actions

For CC homozygotes, the standard lipid landscape is normal HL activity and typically lower HDL-C. Exercise training — particularly aerobic work — reliably raises HDL-C via LPL upregulation, and the Framingham data suggest moderate dietary fat (30-40% of calories) does not negatively affect HDL in this genotype.

For CT heterozygotes, the picture is intermediate: somewhat elevated HDL-C, moderately reduced HL activity. Saturated fat intake is less problematic than in TT homozygotes, but monitoring triglycerides alongside HDL gives a more complete picture.

For TT homozygotes, the key actionable insight is dietary fat composition. Saturated and monounsaturated fat appear to specifically worsen the cardiometabolic profile in this genotype. A lower animal-fat diet (<25% total fat, emphasizing polyunsaturated omega-3 sources) preserves the HDL advantage conferred by the T allele. On a high-animal-fat diet, TT individuals lose their HDL-C benefit and face worsened triglycerides — a combination that increases cardiovascular risk beyond what either factor alone would suggest. Standard lipid panels may be misleading: high HDL-C does not guarantee cardiovascular protection in this genotype, making particle size testing (NMR lipoprofile or apoA-I measurement) more informative than total HDL-C alone.

Interactions

The -514C>T variant is in near-perfect LD with rs2070895 (-250G>A), so genetic tests that report one will effectively capture the other. Related SNPs rs1077835 (-763A>G) and rs1077834 (-710C>T) travel in the same haplotype block.

The CETP Taq1B variant (rs708272) provides a useful contrast. Both LIPC rs1800588 and CETP rs708272 raise HDL-C, but studies show the CETP variant reduces coronary artery disease risk while the LIPC variant does not1010 studies show the CETP variant reduces coronary artery disease risk while the LIPC variant does not — despite both elevating total HDL-C. When both variants are present, the net lipid effect is additive for HDL-C, but the cardiovascular benefit appears to derive primarily from the CETP side of the interaction.

Interaction with LPL variants (particularly rs328 and rs10096633) may modify the triglyceride clearance phenotype. Carriers of high-activity LPL variants who also carry LIPC T alleles may partially compensate for HL deficiency through enhanced peripheral VLDL-TG clearance, producing a more favorable lipoprotein profile than either variant alone would suggest.

Nutrient Interactions

saturated fat altered_metabolism
monounsaturated fat altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Full Hepatic Lipase Activity Normal

Normal hepatic lipase activity and standard lipid metabolism

You carry two C alleles at rs1800588, meaning your LIPC promoter drives normal hepatic lipase production. About 45% of people globally share this genotype (about 62% of Europeans). Your hepatic lipase activity is in the typical range, producing standard HDL-C levels and efficient remodeling of HDL2 to HDL3 particles. This is the reference genotype against which the T allele effects are measured. Regular aerobic exercise reliably raises your HDL-C through lipoprotein lipase upregulation, and your lipid profile responds predictably to standard lifestyle interventions.

CT Reduced Hepatic Lipase Activity Intermediate

Moderately reduced hepatic lipase activity with mildly elevated HDL-C

You carry one T allele at rs1800588. About 44% of people globally share this genotype. Compared to CC individuals, your hepatic lipase activity is reduced by roughly half the effect seen in TT homozygotes — approximately -5.8 mmol/L·h. This translates to modestly higher HDL-C (averaging +0.04 mmol/L or about +1.5 mg/dL) and a slight shift toward larger HDL2 particles. Your lipid panel appears generally favorable, though triglycerides may trend mildly higher. Saturated fat tolerance is intermediate between CC and TT genotypes.

TT Low Hepatic Lipase Activity Reduced

Substantially reduced hepatic lipase activity — HDL-C elevated but diet-dependent

The paradox of your genotype is that what looks like a favorable lipid panel may not translate to cardiovascular protection. Large HDL2 particles that accumulate due to reduced HL activity are less efficient at accepting cholesterol from arterial walls than the smaller, denser HDL3 particles that active HL produces. A physical activity study of over 14,000 women found no reduction in myocardial infarction for LIPC T allele carriers despite meaningfully higher HDL-C.

The Framingham Study (2,130 subjects) showed that at saturated fat intakes above 30% of calories, TT individuals had the lowest HDL-C of any genotype — entirely inverting the expected pattern. A crossover dietary trial confirmed this: TT individuals showed no HDL-C change between high-fat and low-fat diets, while CC and CT carriers benefited from the higher-fat diet. An additional cross-sectional finding showed that saturated fat is specifically unfavorable for HDL-C and triglycerides in TT women — a gene-diet interaction documented across multiple populations.

In a Mexican cohort of 1,468 people, TT homozygotes showed excess risk for type 2 diabetes (OR 1.42), hypertriglyceridemia (OR 1.36), and coronary artery calcification (OR 1.44) compared to CC carriers, despite also showing reduced risk of low HDL. This combination — elevated HDL-C but worsened triglycerides, glucose tolerance, and calcification — captures the complex, mixed cardiometabolic profile of this genotype.

A standard lipid panel can be misleading for TT individuals. Elevated HDL-C from HL deficiency and elevated HDL-C from efficient reverse cholesterol transport look identical on a cholesterol measurement, but have different cardiovascular implications. Direct HDL particle measurement (NMR or apolipoprotein A-I) gives a cleaner signal about functional HDL capacity.